Exicure Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference
Exicure, Inc. (Nasdaq: XCUR) announced that CEO David Giljohann will present at the 2021 H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available for registered attendees to view on-demand starting March 9, 2021, at 7:00 AM EST, and it will be archived for 90 days. Exicure is a biotechnology firm focusing on gene regulatory therapies using its proprietary Spherical Nucleic Acid (SNA) technology, currently in preclinical development for Friedreich’s ataxia and advancing in clinical trials for solid tumors.
- CEO's participation in a prominent life sciences conference could enhance investor visibility.
- Company's SNA technology is positioned as innovative in targeting diseases.
- Ongoing clinical trial for AST-008 with potential market impact.
- None.
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced that CEO David Giljohann will present at the 2021 H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021.
The presentation will be available to registered conference attendees for on-demand viewing beginning March 9, 2021 at 7:00AM EST via the virtual conference link, and will be archived for 90 days.
Exicure will be taking 1x1 investor meetings with registered conference attendees.
Replays of the presentation will be available on Exicure’s website for 30 days following the presentation.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN an SNA–based therapeutic candidate, for the treatment of Friedreich’s ataxia (FA). Exicure's drug candidate AST-008 is currently in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is in Chicago, IL and has an office in Cambridge, MA.
For more information, visit Exicure’s website at www.exicuretx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005074/en/
FAQ
What will Exicure present at the H.C. Wainwright Global Life Sciences Conference?
When can attendees watch Exicure's presentation?
How long will the presentation be available for viewing?
What is Exicure's stock symbol?
What is Exicure's focus in biotechnology?
